



Claims:

1. Compound of the formula (I) or (II)



where

(A) R^1 in formula (I) is substituted or unsubstituted oxazolyl, indolyl, pyrrolyl, pyrazolyl, triazinyl, 2-oxodihydrobenzo[d][1,3]oxazinyl, 4-oxodihydroimidazolyl, 5-oxo-4H-[1,2,4]triazinyl, 3-oxo-4H-benzo[1,4]thiazinyl, tetrahydroquinoxalyl, 1,1,3-trioxodihydro-2H-1 λ^6 -benzo[1,4]thiazinyl, 1-oxo-pyridyl, dihydro-2H-benzo[1,4]oxazinyl, 2-oxotetrahydrobenzo[e][1,4]diazepinyl, 2-oxodihydrobenzo[e][1,4]diazepinyl, 1H-pyrroliziny, phthalazinyl, 1-oxo-3H-isobenzofuranyl, 4-oxo-3H-thieno[2,3-d]pyrimidinyl, 3-oxo-4H-benzo[1,4]oxazinyl, [1,5]naphthyridyl, dihydro-2H-benzo[1,4]thiazinyl, 1,1-dioxodihydro-2H-benzo[1,4]thiazinyl, 2-oxo-1H-pyrido[2,3-b][1,4]oxazinyl, dihydro-1H-pyrido[2,3-b][1,4]oxazinyl, 1H-pyrrolo[2,3-b]pyridyl, benzo[1,3]dioxolyl, benzooxazolyl, 2-oxobenzooxazolyl, 2-oxo-1,3-dihydroindolyl, 2,3-dihydroindolyl, indazolyl, benzofuranyl, dihydrobenzofuranyl, tetrahydropyranyl, 2-oxopiperidinyl or 2-oxoazepanyl; or

(B) R^1 in formula (I) is aryl or heterocyclyl which is substituted by at least one substituent selected from C_{1-6} -alkoxy- C_{1-6} -alkoxy- C_{1-6} -alkyl, C_{3-8} -cycloalkyl- C_{1-6} -alkyl, C_{1-6} -alkoxycarbonyl, C_{0-6} -alkylcarbonylamino, C_{0-6} -alkylcarbonylamino- C_{1-6} -alkyl, C_{0-6} -alkylcarbonylamino- C_{1-6} -alkoxy, (N- C_{1-6} -alkyl)- C_{0-6} -alkylcarbonylamino- C_{1-6} -alkyl, (N- C_{1-6} -alkyl)- C_{0-6} -alkylcarbonylamino- C_{1-6} -alkoxy, C_{3-8} -cycloalkylcarbonylamino- C_{1-6} -alkyl, C_{3-8} -cycloalkylcarbonylamino- C_{1-6} -alkoxy, C_{1-6} -alkoxy- C_{1-6} -alkyl, hydroxy- C_{1-6} -alkyl, hydroxy- C_{1-6} -alkoxy- C_{1-6} -alkyl, hydroxy- C_{1-6} -alkoxy- C_{1-6} -alkoxy, C_{1-6} -alkoxycarbonylamino- C_{1-6} -alkyl, C_{1-6} -alkoxycarbonylamino- C_{1-6} -alkoxy, C_{1-6} -alkylaminocarbonylamino- C_{1-6} -alkyl, C_{1-6} -alkylaminocarbonylamino- C_{1-6} -alkoxy, C_{1-6} -alkylaminocarbonyl- C_{1-6} -alkyl, C_{1-6} -alkylaminocarbonyl- C_{1-6} -alkoxy, C_{1-6} -alkylaminocarbonyl- C_{1-6} -alkoxy- C_{1-6} -alkyl, di- C_{1-6} -alkylaminocarbonyl- C_{1-6} -alkyl, di- C_{1-6} -alkylaminocarbonyl- C_{1-6} -alkoxy, C_{1-6} -alkylcarbonyloxy- C_{1-6} -alkyl, C_{1-6} -alkoxycarbonyloxy- C_{1-6} -alkyl, C_{1-6} -alkylcarbonyloxy- C_{1-6} -alkoxy, cyano- C_{1-6} -alkyl, cyano- C_{1-6} -alkoxy, C_{1-6} -alkoxycarbonyl- C_{1-6} -alkyl, C_{1-6} -alkoxycarbonyl- C_{1-6} -alkoxy, C_{1-6} -alkylsulphonylamino- C_{1-6} -alkyl, C_{1-6} -alkylsulphonylamino- C_{1-6} -alkoxy, (N- C_{1-6} -alkyl)- C_{1-6} -alkylsulphonylamino- C_{1-6} -alkyl, (N- C_{1-6} -alkyl)- C_{1-6} -alkylsulphonylamino- C_{1-6} -alkoxy, amino- C_{1-6} -alkyl, amino- C_{1-6} -alkoxy, C_{1-6} -alkylamino- C_{1-6} -alkyl, C_{1-6} -alkylamino- C_{1-6} -alkoxy, di- C_{1-6} -alkylamino- C_{1-6} -alkyl, di- C_{1-6} -alkylamino- C_{1-6} -alkoxy, C_{1-6} -alkylsulphonyl- C_{1-6} -alkyl, C_{1-6} -alkylsulphonyl- C_{1-6} -alkoxy, carboxy- C_{1-6} -alkyl, carboxy- C_{1-6} -alkoxy, carboxy- C_{1-6} -alkoxy- C_{1-6} -alkyl, C_{1-6} -alkoxy- C_{1-6} -alkylcarbonyl,

acyl-C₁₋₆-alkoxy-C₁₋₆-alkyl, (N-C₁₋₆-alkyl)-C₁₋₆-alkoxycarbonylamino, (N-hydroxy)-C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkyl, (N-hydroxy)-C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkoxy, (N-hydroxy)aminocarbonyl-C₁₋₆-alkyl, (N-hydroxy)aminocarbonyl-C₁₋₆-alkoxy, C₁₋₆-alkoxyaminocarbonyl-C₁₋₆-alkyl, C₁₋₆-alkoxyaminocarbonyl-C₁₋₆-alkoxy, (N-C₁₋₆-alkoxy)-C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkyl, (N-C₁₋₆-alkoxy)-C₁₋₆-alkylaminocarbonyl-C₁₋₆-alkoxy, (N-acyl)-C₁₋₆-alkoxy-C₁₋₆-alkylamino, C₁₋₆-alkoxy-C₁₋₆-alkylcarbonyl, (N-C₁₋₆-alkyl)-C₁₋₆-alkoxy-C₁₋₆-alkylcarbonyl, C₁₋₆-alkoxy-C₁₋₆-alkylcarbonyl, C₁₋₆-alkoxy-C₁₋₆-alkylcarbonylamino, (N-C₁₋₆-alkyl)-C₁₋₆-alkoxy-C₁₋₆-alkylcarbonylamino, carbamoyl-C₁₋₆-alkyl, carbamoyl-C₁₋₆-alkoxy, C₁₋₆-alkylcarbonyl, di-C₁₋₆-alkylcarbonyl, C₁₋₆-alkylsulphonyl, C₁₋₆-alkylamidinyl, acetamidinyl-C₁₋₆-alkyl, O-methyloximyl-C₁₋₆-alkyl and O,N-dimethylhydroxylamino-C₁₋₆-alkyl; or

(C) R¹ in formula (I) is aryl or heterocyclyl which is substituted by at least one substituent selected from [1,2,4]-triazol-1-ylalkyl, [1,2,4]-triazol-1-ylalkoxy, [1,2,4]-triazol-4-ylalkyl, [1,2,4]-triazol-4-ylalkoxy, [1,2,4]-oxadiazol-5-ylalkyl, [1,2,4]-oxadiazol-5-ylalkoxy, 3-methyl-[1,2,4]-oxadiazol-5-ylalkyl, 3-methyl-[1,2,4]-oxadiazol-5-ylalkoxy, 5-methyl-[1,2,4]-oxadiazol-3-ylalkyl, 5-methyl-[1,2,4]-oxadiazol-3-ylalkoxy, tetrazol-1-ylalkyl, tetrazol-1-ylalkoxy, tetrazol-2-ylalkyl, tetrazol-2-ylalkoxy, tetrazol-5-ylalkyl, tetrazol-5-ylalkoxy, 5-methyltetrazol-1-ylalkyl, 5-methyltetrazol-1-ylalkoxy, thiazol-4-ylalkyl, thiazol-4-ylalkoxy, oxazol-4-ylalkyl, oxazol-4-ylalkoxy, 2-oxopyrrolidinylalkyl, 2-oxopyrrolidinylalkoxy, imidazolylalkyl, imidazolylalkoxy, 2-methylimidazolylalkyl, 2-methylimidazolylalkoxy, dioxolanyl, dioxanyl, dithiolanyl, dithianyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrrolyl, 4-methylpiperazinyl, morpholinyl, thiomorpholinyl, 2-hydroxymethylpyrrolidinyl, 3-hydroxypyrrolidinyl, 3,4-dihydroxypyrrolidinyl, 3-acetamidomethylpyrrolidinyl, 3-C₁₋₆-alkoxy-C₁₋₆-alkylpyrrolidinyl, 4-hydroxypiperidinyl, 4-oxopiperidinyl, 3,5-dimethylmorpholinyl, 4,4-dioxothiomorpholinyl, 4-oxothiomorpholinyl, 2,6-dimethylmorpholinyl, 2-oxoimidazolidinyl, 2-oxooxazolidinyl, 2-oxopyrrolidinyl, 2-oxo-[1,3]oxazinyl, 2-oxotetrahydropyrimidinyl, 2-oxooxazolidinyl-C₁₋₆-alkyl, 2-oxooxazolidinyl-C₁₋₆-alkoxy, 1-C₁₋₆-alkoxy-C₁₋₆-alkylimidazol-2-yl, 1-C₁₋₆-alkoxy-C₁₋₆-alkyltetrazol-5-yl, 5-C₁₋₆-alkoxy-C₁₋₆-alkyltetrazol-1-yl and 2-C₁₋₆-alkoxy-C₁₋₆-alkyl-4-oxoimidazol-1-yl; or

(D) R¹ in formula (I) is aryl or heterocyclyl if n is 0 and X is -O-CH-R¹¹-CO-NR⁹-, or if n and m are each 0 and X is -O-CH-R¹¹- and R² is phenyl substituted by C₁₋₆-alkoxybenzyloxy-C₁₋₆-alkoxy; or

(E) R¹ in formula (I) is aryl or heterocyclyl if n is 1 and Z is -alk-NR⁹-, where alk is C₁₋₆-alkylene; or

(F) R¹ in formula (I) is aryl or heterocyclyl when R² is tetrazolyl or imidazolyl which may be substituted by 1-3 halogen, hydroxyl, cyano, trifluoromethyl, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, C₁₋₆-alkoxy-C₁₋₆-alkyl, cyano-C₁₋₆-alkyl, carboxy-C₁₋₆-alkyl, C₁₋₆-alkanoyloxy-C₁₋₆-alkyl, C₁₋₆-alkoxycarbonyloxy-C₁₋₆-alkyl, C₁₋₆-alkoxycarbonyl, or C₁₋₆-alkoxy groups, or a C₁₋₆-alkylenedioxy group, and/or may be substituted by an L1-T1-L2-T2-L3-T3-L4-T4-L5-U radical; or

(G) R¹ in formula (II) is aryl or heterocyclyl;

R^2 is phenyl, naphthyl, acenaphthyl, cyclohexyl, pyridyl, pyrimidinyl, pyrazinyl, oxopyridinyl, diazinyl, triazolyl, thienyl, oxazolyl, oxadiazolyl, thiazolyl, pyrrolyl, furyl, tetrazolyl or imidazolyl which radicals may be substituted by 1-3 halogen, hydroxyl, cyano, trifluoromethyl, C_{1-6} -alkyl, halo- C_{1-6} -alkyl, hydroxy- C_{1-6} -alkyl, C_{1-6} -alkoxy- C_{1-6} -alkyl, cyano- C_{1-6} -alkyl, carboxy- C_{1-6} -alkyl, C_{1-6} -alkanoyloxy- C_{1-6} -alkyl, C_{1-6} -alkoxycarbonyloxy- C_{1-6} -alkyl, C_{1-6} -alkoxycarbonyl, or C_{1-6} -alkoxy groups, or a C_{1-6} -alkylenedioxy group, and/or by an L1-T1-L2-T2-L3-T3-L4-T4-L5-U radical;

L1, L2, L3, L4 and L5 are each independently a bond, C_{1-8} -alkylene, C_{2-8} -alkenylene or C_{2-8} -alkynylene, or are absent;

T1, T2, T3 and T4 are each independently

(a) a bond, or are absent, or are one of the groups

(b) $-CH(OH)-$

(c) $-CH(OR^6)-$

(d) $-CH(NR^5R^6)-$

(e) $-CO-$

(f) $-CR^7R^8-$

(g) $-O-$ or $-NR^6-$

(h) $-S(O)_{0-2}-$

(i) $-SO_2NR^6-$

(j) $-NR^6SO_2-$

(k) $-CONR^6-$

(l) $-NR^6CO-$

(m) $-O-CO-$

(n) $-CO-O-$

(o) $-O-CO-O-$

(p) $-O-CO-NR^6-$

(q) $-N(R^6)-CO-N(R^6)-$

(r) $-N(R^6)-CO-O-$

(s) pyrrolidinylene, piperidinylene or piperazinylene

(t) $-C(R^{11})(R^{12})-$,

where the bonds starting from (b)-(t) lead to a saturated or aromatic carbon atom of the adjacent group if the bond starts from a heteroatom, and where not more than two (b)-(f) groups, three (g)-(h) groups and one (i)-(t) group are present;

R^3 is hydrogen, hydroxyl, C_{1-6} -alkoxy or C_{2-6} -alkenyloxy;

R^4 is hydrogen, C_{1-6} -alkyl, C_{2-6} -alkenyl, C_{1-6} -alkoxy, hydroxy- C_{1-6} -alkyl, C_{1-6} -alkoxy- C_{1-6} -alkyl, benzyl, oxo, or a

R^{4a} -Z1-X1- group where R^{4a} is

(a) H-

(b) C_{1-6} -alkyl-

- 242 -

- (c) C₂₋₆-alkenyl-
- (d) hydroxy-C₁₋₆-alkyl-
- (e) polyhydroxy-C₁₋₆-alkyl-
- (f) C₁₋₆-alkyl-O-C₁₋₆-alkyl-
- (g) aryl-
- (h) heterocyclyl-
- (i) arylalkyl-
- (j) heterocyclylalkyl-
- (k) aryloxyalkyl-
- (l) heterocyclioxyalkyl-
- (m) (R⁵, R⁶)N-(CH₂)₁₋₃-
- (n) (R⁵, R⁶)N-
- (o) C₁₋₆-alkyl-S(O)₀₋₂-
- (p) aryl-S(O)₀₋₂-
- (q) heterocyclyl-S(O)₀₋₂-
- (r) HO-SO₃- or salts thereof
- (s) H₂N-C(NH)-NH-
- (t) NC-

and the bonds starting from (n)-(t) lead to a carbon atom of the adjacent group and this carbon atom is saturated if the bond starts from a heteroatom;

Z1

- (a) is a bond, is absent, or is one of the groups
- (b) C₁₋₆-alkylene-
- (c) C₂₋₆-alkenylene-
- (d) -O-, -N(R¹¹)-, -S(O)₀₋₂-
- (e) -CO-
- (f) -O-CO-
- (g) -O-CO-O-
- (h) -O-CO-N(R¹¹)-
- (i) -N(R¹¹)-CO-O-
- (j) -CO-N(R¹¹)-
- (k) -N(R¹¹)-CO-
- (l) -N(R¹¹)-CO-N(R¹¹)-
- (m) -CH(OR⁹)-

and the bonds starting from (d) and (f)-(m) lead to a carbon atom of the adjacent group and this carbon atom is saturated if the bond starts from a heteroatom;

X1

- (a) is a bond, is absent, or is one of the groups
- (b) -O-

(c) $-N(R^{11})-$

(d) $-S(O)_{0-2}-$

(e) $-(CH_2)_{1-3}-$

or R^3 and R^4 in formula (I) together are a bond;

R^5 and R^6 are each independently hydrogen, C_{1-6} -alkyl, C_{2-6} -alkenyl, aryl- C_{1-6} -alkyl or acyl, or, together with the nitrogen atom to which they are bonded, are a 5- or 6-membered heterocyclic ring which may contain an additional nitrogen, oxygen or sulphur atom or a $-SO-$ or $-SO_2-$ group, and the additional nitrogen atom may optionally be substituted by C_{1-6} -alkyl radicals;

R^7 and R^8 , together with the carbon atom to which they are bonded, are a 3-7-membered ring which may contain one or two $-O-$ or $-S-$ atoms or $-SO-$ or $-SO_2-$ groups;

R^9 is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy- C_{1-6} -alkyl, acyl or arylalkyl;

R^{10} is carboxyalkyl, alkoxycarbonylalkyl, alkyl or hydrogen;

R^{11} is hydrogen or C_{1-6} -alkyl;

R^{12} is hydrogen or C_{1-6} -alkyl;

U is hydrogen, C_{1-6} -alkyl, C_{3-8} -cycloalkyl, cyano, optionally substituted C_{3-8} -cycloalkyl, aryl, or heterocyclyl;

Q is ethylene or is absent (formula I) or is ethylene or methylene (formula II);

X is a bond, oxygen or sulphur, or is a $>CH-R^{11}$, $>CHOR^9$, $-O-CO-$, $>CO$, $>C=NOR^{10}$, $-O-CHR^{11}-$ or $-O-CHR^{11}-CO-NR^9-$ group and the bond starting from an oxygen or sulphur atom leads to a saturated carbon atom of the Z group or to R^1 ;

W is oxygen or sulphur;

Z is C_{1-6} -alkylene, C_{2-6} -alkenylene, hydroxy- C_{1-6} -alkylidene, $-O-$, $-S-$, $-O-alk-$, $-S-alk-$, $-alk-O-$, $-alk-S-$ or $-alk-NR^9-$, where alk is C_{1-6} -alkylene; and where

(a) if Z is $-O-$ or $-S-$, X is $>CH-R^{11}$ and either R^2 contains an L1-T1-L2-T2-L3-T3-L4-T4-L5-U substituent or R^4 is a substituent other than hydrogen as defined above;

(b) if Z is $-O-alk-$ or $-S-alk-$, X is $>CH-R^{11}$; and



(c) if X is a bond, Z is C_{2-6} -alkenylene, $-alk-O-$ or $-alk-S-$,

n is 0 or 1;

m is 0 or 1;

and pharmaceutically usable salts thereof.

2. Compound according to Claim 1 of the formula (IA) or (IIA)



where R^1 , R^2 , R^3 , R^4 , Q , W , X , Z , n and m are each as defined for the compounds of the formulae (I) or (II) according to Claim 1.

3. Compound according to Claim 1 or 2 where

R^1 is as defined for (A), (B), (C), (D), (E), (F) or (G), more preferably as specified for (A), (B), (C) or (D); R^2 is phenyl, cyclohexyl, tetrazolyl, unsubstituted or substituted by halogen, hydroxyl, cyano, trifluoromethyl, C_{1-6} -alkyl, halo- C_{1-6} -alkyl, hydroxy- C_{1-6} -alkyl, C_{1-6} -alkoxy- C_{1-6} -alkyl, cyano- C_{1-6} -alkyl, carboxy- C_{1-6} -alkyl, C_{1-6} -alkanoyloxy- C_{1-6} -alkyl, C_{1-6} -alkoxycarbonyloxy- C_{1-6} -alkyl, C_{1-6} -alkoxycarbonyl, C_{1-6} -alkoxy, C_{1-6} -alkylenedioxy, or by an L1-T1-L2-T2-L3-T3-L4-T4-L5-U radical; or naphthyl or acenaphthyl;

L1, L2, L3, L4 and L5 are each independently a bond, C_{1-8} -alkylene, C_{2-8} -alkenylene or C_{2-8} -alkynylene, or are absent;

T1, T2, T3 and T4 are each independently

(a) a bond, or are absent, or are one of the groups

(b) $-\text{CH}(\text{OH})-$

(c) $-\text{CH}(\text{OR}^6)-$

(d) $-\text{CH}(\text{NR}^5\text{R}^6)-$

(e) $-\text{CO}-$

(f) $-\text{CR}^7\text{R}^8-$

(g) $-\text{O}-$ or $-\text{NR}^6-$

(h) $-\text{S}(\text{O})_{0-2}-$

(i) $-\text{SO}_2\text{NR}^6-$

(j) $-\text{NR}^6\text{SO}_2-$

(k) $-\text{CONR}^6-$

(l) $-\text{NR}^6\text{CO}-$

(m) $-\text{O}-\text{CO}-$

(n) $-\text{CO}-\text{O}-$

(o) $-\text{O}-\text{CO}-\text{O}-$

(p) $-\text{O}-\text{CO}-\text{NR}^6-$

(q) $-\text{N}(\text{R}^6)-\text{CO}-\text{N}(\text{R}^6)-$

(r) $-\text{N}(\text{R}^6)-\text{CO}-\text{O}-$

(s) pyrrolidinylene, piperidinylene or piperazinylene

(t) $-\text{C}(\text{R}^{11})(\text{R}^{12})-$,

where the bonds starting from (b)-(t) lead to a saturated or aromatic carbon atom of the adjacent group if the bond starts from a heteroatom, and where not more than two (b)-(f) groups, three (g)-(h) groups and one (i)-(t) group are present;

R³ is hydrogen, hydroxyl, C₁₋₆-alkoxy or C₂₋₆-alkenyloxy;

R⁴ is hydrogen, C₁₋₆-alkyl, C₂₋₆-alkenyl, C₁₋₆-alkoxy, hydroxy-C₁₋₆-alkyl, C₁₋₆-alkoxy-C₁₋₆-alkyl or benzyl;

R⁵ and R⁶ are each independently hydrogen, C₁₋₆-alkyl or acyl, or, together with the nitrogen atom to which they are bonded, are a 5- or 6-membered heterocyclic ring which may contain an additional nitrogen, oxygen or sulphur atom;

R⁷ and R⁸, together with the carbon atom to which they are bonded, are a 3-7-membered ring which may contain one or two -O- or -S- atoms;

R⁹ is hydrogen, C₁₋₆-alkyl, acyl or arylalkyl;

U is hydrogen, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, cyano, aryl or heterocyclyl;

Q is ethylene or is absent (formula (I)) and is ethylene or methylene (formula (II));

X is oxygen, sulphur or a >CH₂, >CHOR⁹, -O-CO-, >CO or -O-CH-R¹¹-CO-NR⁹- group;

W is oxygen or sulphur if R³ is hydrogen;

Z is C₁₋₆-alkylene or -alk-O-;

n is 0 or 1;

m is 0 or 1;

and pharmaceutically useable salts thereof.

4. Compound according to Claim 1, wherein R¹ is 3-C₁₋₆-alkylindolyl, benzofuranyl, 4H-benzo[1,4]oxazin-3-onyl, 3,4-dihydro-2H-benzo[1,4]oxazinyl, 3,4-dihydro-2H-benzo[1,4]thiazinyl, 3,3-di-C₁₋₆-alkyl-1,3-dihydroindol-2-onyl, 3,3-di-C₁₋₆-alkyl-1,3-dihydroindolyl, indolyl, 3-methylindolyl and spiro[cyclopropane-1,3]-2,3-dihydro-1H-indolyl, each of which may in particular be substituted by at least one substituent selected from C₁₋₆-alkoxy-C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl, N-acetyl-C₁₋₆-alkoxy-C₁₋₆-alkylamino, C₁₋₆-alkanoylamido-C₁₋₆-alkyl, N-C₁₋₆-alkyl-C₁₋₆-alkanoylamido-C₁₋₆-alkyl, C₁₋₆-alkoxy-C₁₋₆-alkoxy-C₁₋₆-alkyl, triazol-1-yl-C₁₋₆-alkyl, tetrazol-1-yl-C₁₋₆-alkyl, tetrazol-2-yl-C₁₋₆-alkyl, tetrazol-5-yl-C₁₋₆-alkyl, C₁₋₆-alkoxycarboxyl-C₁₋₆-alkyl, pyrrolidinonyl-C₁₋₆-alkyl, imidazolyl-C₁₋₆-alkyl, cyano-C₁₋₆-alkyl, carboxy-C₁₋₆-alkyl, carboxy-C₁₋₆-alkoxy, C₁₋₆-alkoxycarbonyl-C₀₋₆-alkyl, C₁₋₆-alkylsulphonamidyl-C₁₋₆-alkyl, C₁₋₆-alkoxy-C₁₋₆-alkanoylamido, C₁₋₆-alkoxy-C₁₋₆-alkanoylamido-C₁₋₆-alkyl, N-(C₁₋₆-alkyl)-C₁₋₆-alkoxy-C₁₋₆-alkanoylamido, N-C₁₋₆-alkylcarbamoyl-C₁₋₆-alkyl, C₃₋₈-cycloalkanoylamido-C₁₋₆-alkyl, C₁₋₆-alkylaminocarbonylamino-C₁₋₆-alkyl, C₁₋₆-alkanoylamidomethylpyrrolidinyl, N-(C₁₋₆-alkoxy-C₁₋₆-alkyl)carbamoyl, N-(C₁₋₆-alkoxy-C₁₋₆-alkyl)-N-(C₁₋₆-alkyl)carbamoyl, N-(C₁₋₆-alkoxy-C₁₋₆-alkyl)imidazol-2-yl, hydroxy-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkoxy, hydroxy-C₁₋₆-alkoxy-C₁₋₆-alkyl, C₁₋₆-alkoxycarbonylamido-C₁₋₆-alkyl, amino-C₁₋₆-alkyl and C₁₋₆-alkylamino-C₁₋₆-alkyl.

5. Compound according to Claim 1, wherein R^2 is phenyl or halophenyl each substituted by C_{1-6} -alkoxybenzyloxy- C_{1-6} -alkoxy, C_{1-6} -alkoxyphenyl- C_{1-6} -alkoxy- C_{1-6} -alkoxy, C_{1-6} -alkylphenoxy- C_{1-6} -alkoxy, halobenzyloxy- C_{1-6} -alkoxy, halophenoxy- C_{1-6} -alkoxy, halophenoxy- C_{1-6} -alkoxy- C_{1-6} -alkyl, N-(halophenyl)pyrrolidin-3-yloxy or indol-4-yloxy- C_{1-6} -alkyl.
6. Compound according to Claim 1, wherein X is hydrogen, $-O-CH_2-CO-NH-$, $-O-CH_2-CO-N(CH_3)-$ or $-O-CH(CH_3)-CO-NH-$.
7. Compound according to Claim 1, wherein Z is methylene, $-(CH_2)_2-O-$ or $-CH(CH_3)-$.
8. Pharmaceutical preparations comprising a compound of the formula (I), (IA), (II) or (IIA) according to Claims 1 and 2.
9. Use of a compound of the formula (I), (IA), (II) or (IIA) according to Claims 1 and 2 in the treatment or prevention of hypertension, heart failure, glaucoma, cardiac infarction, kidney failure or restenoses.
10. Use of a compound of the formula (I), (IA), (II) or (IIA) according to Claims 1 and 2 for the preparation of a medicament, preferably a medicament for the treatment or prevention of hypertension, heart failure, glaucoma, cardiac infarction, kidney failure or restenoses.